1	Evaluation of	population	immunity	against SARS-Co	V-2 variants.	EG.5.1.	FY.4.	BA.2.86.
-		population	I I I I I I I I I I I I I I I I I I I			10.011		

- 2 JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya.
- 3 Doreen Lugano^{1*}, Bernadette Kutima^{1*}, Makobu Kimani¹, Antipa Sigilai¹, John Gitonga¹,
- 4 Angela Karani¹, Donald Akech¹, Boniface Karia¹, Abdhalah K. Ziraba⁴, Angela Maina¹, Arnold
- 5 Lambisia¹, Donwilliams Omuoyo¹, Daisy Mugo¹, Ruth Lucinde¹, Joseph Newman⁵, Dalan
- 6 Bailey ⁵, Eunice Nduati ¹, George Githinji ¹, Charles N. Agoti ¹, Philip Bejon ^{1, 3}, J Anthony G
- 7 Scott ^{1, 2}, Ambrose Agweyu ^{1, 2}, Wangeci Kagucia ¹, George M Warimwe ^{1, 3}, Charles Sande ¹,
- 8 Lynette I Ochola-Oyier^{1*}, James Nyagwange^{1*+}
- 9 ¹ KEMRI-Wellcome Trust Research Programme, P.O. Box 230 Kilifi, Kenya
- 10 ² Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical
- 11 Medicine, WC1E 7HT, Keppel Street, London, United Kingdom
- ³ Nuffield Department of Medicine, Oxford University, OX3 7BN, Oxford, United Kingdom
- ⁴ African Population and Health Research Center, APHRC Campus, Manga Close, Kitisuru
- 14 Nairobi, P.O. Box 10787, 00100 Nairobi, Kenya
- ⁵ The Pirbright Institute, Ash Road, Woking, GU24 0NF, Surrey, United Kingdom
- 16 *Authors contributed equally
- ¹⁷ ⁺Corresponding author at KEMRI-Wellcome Trust Research Programme P.O. Box 230 Kilifi.
- 18 Email: jnyagwange@kemri-wellcome.org
- 19
- 20
- 21

22 Abstract

23	Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a
24	key challenge to the control of COVID-19. The majority of these mutations mainly target the
25	spike protein, allowing the new variants to escape the immunity previously raised by vaccination
26	and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the
27	neutralizing capacity of antibodies against emerging variants of interest circulating between May
28	2023 and March 2024 using sera from representative samples of the Kenyan population. From
29	our genomics data, we identified the most prevalent Kenyan and global variants and performed
30	pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show
31	that antibodies from individuals in the general population in Kenya were less effective against
32	the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and
33	JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization
34	following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not
35	neutralize the omicron variants, suggesting that individuals were susceptible to infection by these
36	variants.

37 Keywords: SARS-CoV-2 variants, vaccination, neutralization, population immunity

38

39

41 Introduction

42	The emergence of new variants, recurring natural infection, vaccine efficacy, and
43	specificity and longevity of neutralizing antibodies are key variables determining long-term
44	control of coronavirus disease 2019 (COVID-19) ^{1,2} . Research efforts have focused on finding
45	interventions that can reduce infection and transmission while improving clinical outcomes of
46	COVID-19 in patients ³ . A main strategy is the raising of protective neutralizing antibodies
47	(nAbs) in the host population through vaccination $4-7$. Neutralizing antibodies bind to SARS-
48	CoV-2 structural proteins, especially the spike, inhibiting infection of host cells through the
49	ACE-2 receptor ^{8–10} . However, the virus continues to mutate in the spike protein giving rise to
50	new variants. This makes it unclear to what extent neutralizing antibodies induced by earlier
51	exposure through natural infection and vaccination are protective to the emerging variants and
52	whether mono-variant multiple vaccine dosing improves this outcome.

The first vaccinations in Kenya began in adults in March 2021, and as of May 2022, the 53 54 Ministry of Health reported approximately 8.3 million fully vaccinated adults and 2.5 million partially vaccinated adults ¹¹. This accounted for only 30.7% of the Kenyan adult population 55 being vaccinated and highlights issues with access, vaccine hesitancy due to religious and 56 cultural beliefs, and concerns over safety and efficacy ^{11,12}. Several studies report on vaccine 57 effectiveness in the rapid production of neutralizing antibodies against SARS-CoV-2^{1,2,8-10,13} and 58 similarly, natural infection leads to the development of wildtype and cross-protective nAbs 59 within the first two weeks after infection 1,2 . 60

Emerging SARS-CoV-2 variants have increased mutations targeted to the spike gene, that lead to immune escape phenotypes ^{4,6}. Questions have been raised on whether ancestral strain COVID-19 vaccines are sufficient to counter upcoming variants of concern and interest, and new

64	strategies on access and composition of vaccines are fast changing ^{4,14} . Alternatives such as
65	boosting with monovalent vaccines comprising more recent variants may improve neutralizing
66	antibody function and outcomes of COVID-19 in patients and the World Health Organization
67	Scientific Advisory Group of Experts (WHO-SAGE) recently recommended the development
68	and deployment of JN.1 spike-based vaccines ^{14–17} .
69	Here we used genomic data to identify locally circulating variants in Kenya between May
70	2023 and March 2024 ^{18,19} . We evaluated the neutralizing capacity of antibodies from samples
71	collected from two health demographic surveillance systems in Kenya (n=58), for vaccine-
72	induced immunity against dominant variants EG.5.1, FY.4 ¹⁹ , BA.2.86, JN.1, and JN.1.4. As a
73	comparator, we used natural wildtype infection samples (n=20) collected in 2020 at the onset of
74	the pandemic and confirmed to be PCR positive for SARS-CoV-2. We also assessed the effects
75	of different doses of vaccine, age, sex, and type of vaccine on antibody neutralizing titers.
76	

78 **Results**

79 Circulating SARS-CoV-2 lineages between May 2023 and March 2024.

80	We used genomic data to identify emerging variants of interest in Kenya and globally,
81	between May 2023 and March 2024 ²¹ . The top circulating strains worldwide were XBB.1.5,
82	JN.1, JN.1.4, BA.2.86, EG.5.1.1, (Fig. 1A) whereas XBB.1.5, XBB.1.16, JN.1, JN.1.4, and
83	BA.2.86, were prominent in Europe (Fig. 1B). Kenya's leading strains were FY.4 ¹⁹ , GE.1.2,
84	JN.1, JN.1.4, and JE.1.1 (Fig. 1C). We mapped 616 sequences from samples collected and
85	sequenced in Kenya in a phylogenetic tree. These samples were collected in 17 counties, with the
86	majority being from Nairobi (28%), Kilifi (20%), and Kiambu (13%) counties (Supplementary
87	Fig. 1). We show the predominance of strains FY.4 ¹⁹ , GE.1.2, JN.1, JN.1.4, BQ.1.1, and
88	JE.1.1/KH.1 like variants (Fig. 1D). We performed pseudovirus neutralization assays on
89	circulating strains EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4. FY.4, JN.1, and JN.1.4 were
90	prevalent in Kenya during this period ^{18,19} , while BA.2.86 and EG.5.1 were circulating in nearby
91	regions ^{25–27} .







D.



97

98 Figure 1: SARS-CoV-2 lineage frequency (%) between May 2023 and March 2024.

99 This figure presents worldwide, European, and Kenyan SARS-CoV-2 lineage frequency % maps

100 from GISAID. A. Shows the lineage frequency % in all countries (n = 775112) B. Shows the

101 *lineage frequency % in Europe (n=232081). C. Shows the lineage frequency % in Kenya*

102 (n=616). The legends in A, B, and C show the top circulating variants in each region within the

- 103 *period of interest, with the colors corresponding to the frequency. D. Shows the phylogenetic*
- analysis of 616 sequences collected and sequenced from Kenya between May 2023 and March
- 105 *2024. The legend shows the lineages corresponding to the colors on the tree.*

106 An evaluation of neutralizing function against, wildtype, EG.5.1, FY.4, BA.2.86, JN.1, and

107 JN.1.4, in population-representative samples

108 Table 1: Baseline characteristics of naturally infected and vaccinated cohort used in this

- 109 study. The table provides details of the sex, age, vaccination status, and type of vaccine in this
- 110 cohort.

	AstraZeneca	Pfizer	Johnson &	Moderna	Mixed	Wildtype	Total
	(n=30)	(n=10)	Johnson	(n=6)	(n=2)	Infected	(n=78)
			(n=10)			(n=20)	
Sex							
Male	15 (50%)	2 (20%)	5 (50%)	3 (50%)	0 (0%)	11 (55%)	36
Female	15 (50%)	8 (80%)	5 (50%)	3 (50%)	2 (100%)	9 (45%)	42
Age							
>18-60	24 (80%)	8 (80%)	8 (80%)	5 (83%)	2 (100%)	17 (85%)	64
>60	6 (20%)	2 (20%)	2 (20%)	1 (17%)	0 (0%)	3 (15%)	14
Vaccination							
1 dose	6 (20%)	4 (40%)	10 (100%)	0 (0%)	0 (0%)	0 (0%)	20
2 doses	14 (47%)	3 (30%)	0 (0%)	1 (17%)	1 (50%)	0 (0%)	19
3 doses	10 (33%)	3 (30%)	0 (0%)	5 (83%)	1 (50%)	0 (0%)	19

111

112

Inhibitory dilutions (ID₅₀) of sera from naturally infected (n=20) and vaccinated

individuals (n=58) were used to determine neutralizing antibody function against EG.5.1, FY.4,

114 BA.2.86, JN.1, and JN.1.4 pseudovirus variants. Compared to wildtype pseudovirus where

115 (83%) 65/78 serum samples exhibited neutralization function, only 41/78 (53%) neutralized

116 EG.5.1, 23/78 (29%) neutralized FY.4, 25/78 (32%) neutralized BA.2.86, 29/78 (37%)

neutralized JN.1, and 31/78 (40%) neutralized JN.1.4 (Fig.2A-E). Furthermore, among the

- positives we observed a consistent decline in neutralizing antibody titers against all strains with a
- 119 mean ID₅₀ of 1:613, 1:441, 1:576, 1:530, and 1:532 for EG.5.1, FY.4, BA.2.86, JN.1, and
- JN.1.4, respectively, compared to 1:1155 in wildtype (Fig.2A-E). These differences in ID₅₀ of
- the variants relative to wildtype were statistically significant (p-value <0.0001, Fig.2F).

122







124 Figure 2: A comparison of inhibitory dilutions (ID_{50}) between wildtype and omicron variants

EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, in Kenyan population samples (n=78). A. Represents

125

126	the log ID_{50} between wildtype and EG.5.1 where 41/78 in EG.5.1 showed neutralization. B.
127	Represents the log ID_{50} between wildtype and FY.4 where 23/78 samples showed neutralization.
128	C. Represents the log ID_{50} between wildtype and BA.2.86 where 25/78 samples showed
129	neutralization. D. Represents the log ID_{50} between wildtype and JN.1 where 29/78 samples
130	showed neutralization. E. Represents the log ID_{50} between wildtype and JN.1.4 where 31/78
131	samples showed neutralization. The numbers above each variant plot represent the mean ID_{50}
132	compared to wild type. F. Shows the statistical analysis of ID_{50} between wild type and each
133	variant. A statistical significance of $P < 0.0001$ (***) was recorded between wild type and all
134	strains, based on Mann-Whitney tests. The sample colors represent SARS-CoV-2 variants where
135	red is wildtype, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is
136	JN.1.4. The dotted line represents the cut-off neutralization ID_{50} of 10^{1} .
137	Next, we measured the escape from the existing humoral immunity by these variants after
138	natural infection with the wildtype variant and vaccination with different doses. Neutralization in
139	samples with wildtype natural infection showed that 18/20 (90%) individuals could neutralize the
140	wildtype but only 4/20 (20%) neutralized EG.5.1, 3/20 (15%) neutralized FY.4, 3/20 (15%)

141 neutralized BA.2.86, 3/20 (15%) neutralized JN.1, and 3/20 (15%) neutralized JN.1.4 (Fig.3A).

142 After one dose, there was increased neutralization of 12/20 (60%) in EG.5.1, 5/20 (25%) in

143 FY.4, 4/20 (20%) in BA.2.86, 8/20 (40%) in JN.1, 7/20 (35%) in JN.1.4, and 15/20 in wildtype

- 144 (75%). However, after three doses, there was significant decrease in neutralization function
- against most omicron variants relative to two doses, where 12/19 (63%) individuals for EG.5.1,

3/19 (16%) for FY.4, 7/19 (37%) for BA.2.86, 7/19 (37%) for JN.1, and 8/19(42%) for JN.1.4
(Fig.3B).

148	We then examined whether the age of individuals who received one, two, or three doses
149	of the vaccine affected these findings. From the distribution of ages, we noted that the majority
150	of individuals who received two doses $14/20$ (70%) and three doses $14/19$ (74%) were above 50
151	years (Fig. 3C). Additionally, we determined whether days post-vaccination affected variances in
152	neutralization function. We found that 9/20 (45%) of individuals receiving two doses were
153	within 6 months of vaccination (180 days), whereas only $3/19$ (15%) of individuals with three
154	doses were within this period, which could explain the decline in neutralization (Fig.3D). Lastly,
155	we evaluated the neutralization capacity between male and female participants and the type of
156	vaccine administered and observed no markable changes (Supplementary Fig. 2)



158 Figure 3:Evaluation of naturally- acquired (n=20) and vaccine-induced immunity (n=58) in

- **Kenyan population samples.** A & B. Shows neutralization (log ID₅₀) after natural infection
- 160 (n=20) or vaccination with one dose (n=20), two doses (n=19), and three doses (n=19). The
- 161 *legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4,*
- 162 green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by
- 163 *Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***). The dotted line*
- 164 represents the cut-off neutralization ID_{50} of 10^{1} . C. Represents the distribution of ID_{50} based on
- age between individuals administered with one, two, and three doses of vaccine. The dotted line
- separates individuals below and above 50 years old. D. Shows the distribution based on days
- 167 *post-vaccination with administering one, two, and three vaccine doses. The dotted line represents*
- 168 *a cut-off of 6 months after vaccination.* C & D Circles represent one dose, boxes represent two
- 169 *doses, and triangles represent three boxes.*

170 Discussion

The rapid mutation of the SARS-CoV-2 virus may lead to the emergence of new variants
that evade neutralization by pre-existing antibodies and have increased infectivity,

transmissibility, and pathogenicity ^{28–32}. This study investigated neutralization as a correlate of
protection against emerging variants circulating between May 2023 and March 2024 in a subset
of the Kenya population. We used genomic data from Kenya ^{18–20}, to identify variants circulating
during the study period and performed pseudoviruses neutralization assays.

Genomic data from samples collected in 17 counties in Kenya (Supplementary Fig. 1) showed mostly similar lineage frequencies compared to other regions globally, but there were occasional differences such as predominant circulation of FY.4 and GE.1.2 in the Kenyan population only (Fig. 1 A-C) ^{19,21}. We characterized EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4.

181	FY.4 was first reported in March of 2023 and was prevalent in Kenya, specifically in the coastal
182	region, with a Y451H mutation in the spike and P42L in the ORF3a (Fig. 1C-D) ¹⁹ . Functional
183	changes caused by Y451H remain unknown, but mutations on the ORF3a are linked to loss of
184	CD8+ T cell recognition ¹⁹ . EG.5.1 is a descendant of XBB.1.9.2 lineage which emerged in May
185	2023 and demonstrated substantial growth advantage over predecessor XBB lineages in Europe,
186	Asia, and North America ²⁵ . BA.2.86 was a variant of interest with more than 30 mutations on
187	the spike protein relative to ancestral strain BA.2 and had over 35 mutations compared to
188	XBB.1.5 ^{26,33} . It was first reported in mid-July 2023 and was highly prevalent in Israel, Europe,
189	and the US, and as of November 2023, it was detected in Kenya (Fig. 1A-D). Lastly, JN.1 and
190	JN.1.4 are sub-lineages of BA.2.86 and maintain the hallmark L455S amino acid change on the
191	spike and three key mutations in non-spike regions ²⁵ . These two later strains were the most
192	recent topmost circulating variants in many global regions and were reported to enhance immune
193	evasion properties and increase infectivity ²⁵ .

Surveillance of neutralizing capacity in a subset of population samples allows insights 194 195 into the general immunity and vaccine effectiveness, enabling the generation of better strategies to mitigate future outbreaks ^{15,34}. We observed that most wildtype-induced infections elicited 196 antibodies that could not neutralize the new variants. Interestingly, a few of these antibodies 197 showed neutralization capabilities against the emerging omicron variants, suggesting the 198 presence of cross-protective antibodies and presenting an opportunity for the isolation of cross-199 200 protective monoclonal antibodies for therapeutic use, or inform the design of vaccines that specifically induce cross-reactive antibodies. 201

We have demonstrated that both natural infection and vaccine-induced immunity from the wildtype was neutralizing to the wildtype but non-neutralizing against the emerging omicron

variants. Although there was a substantial boost to neutralizing antibody titers against all new 204 variants after two doses, there was no evidence of further boosting after three doses, and possibly 205 even reductions against some variants. Similar observations have been reported in sera from 3-206 dose mono-valent vaccinated individuals who exhibited non-neutralizing antibodies against 207 BA.2.86, and XBB variants ²⁶. However, in our study cohort, 12/19 (63%) individuals with three 208 doses were above 50 years, and 16/19 (84%) were sampled about 9 months (287 days) post-209 vaccination. Previously, it has been shown that for older individuals the level of protection 210 waned by more than 50 % after three or more doses within 6-9 months ³³. Therefore, the reduced 211 212 neutralization after three doses observed in this study could have been confounded by the age of the cohort, and the longer sampling frame post-vaccination, > 9 months. Nevertheless, the data 213 does not support repeated boosting as a strategy to generate cross-reactive antibodies. 214

Genomic surveillance of SARS-CoV-2 has greatly reduced in Kenya, hence all genomic 215 data in this study represents two-thirds of all geo-specified isolates came from two counties of 216 Kilifi and Nairobi, presenting a limitation of the study in generalization of the Kenya genomic 217 data. Another limitation of this study is the use of convenient cross-sectional samples which 218 219 implies the lack of follow up with participants to understand how pre and post-vaccination 220 infections could affect the neutralization capacity. Therefore, the data presumed as vaccineinduced immunity could be caused by hybrid immunity and the differences could be driven by 221 222 infections by different variants. Some studies have suggested that vaccination and boosting by 223 the wildtype may result in immune imprinting and requirement for multiple boosting with omicron based vaccines to achieve neutralization of the new variants ^{16,35}. However, it is not 224 clear if natural infection could break the imprint to provide protective hybrid immunity. Also 225 unclear is the impact of such imprinting to countries such as Kenya which have majorly 226

administered mono-valent wildtype based vaccines and boosters. Nonetheless, mono-valent
 studies using omicron and its emerging subvariant boosters are in progress and may provide
 clarity in the future ¹⁴.

In conclusion, we demonstrate a decline in naturally acquired and vaccine-induced 230 antibody protection, with the emergence of new omicron variants in a subset of the Kenyan 231 population. This conclusion prompts the need for updated vaccine strategies in the country such 232 233 as boosting by vaccines with currently circulating variants, to counter immune escape as the virus evolves, giving the population a chance to raise protective neutralizing antibodies to 234 circulating variants ^{1415,16,34}. Although we have measured nAbs as a correlate of protection, other 235 236 arms of the immune system may also play a role in the protection against COVID-19, such as Tcells ^{36,37}. Furthermore, the absence of nAbs may not necessarily mean absence of memory B-237 cells which could be quickly mobilized to produce nAbs in case of an infection thereby 238 conferring protection ³⁸. 239

240 Materials and Methods

241 Genomics data

242 Genomics surveillance data from the Kenya Medical Research Institute Wellcome Trust

243 Research Programme (KWTRP), and other sequencing facilities in Kenya were used to

determine locally circulating variants between May 2023 and March 2024^{18–20}. The data

included samples collected from 17 Kenyan counties and sequenced in four Kenyan facilities,

246 KWTRP (57%), Kenya Medical Research Institute- Center for Disease Control and Prevention

247 (KEMRI-CDC) (39%), International Livestock Research Institute (ILRI) (2%), and National

248 Public Health Laboratory (NPHL) (1%). The majority of sequences were from the Nairobi (28%)

and Kilifi Health and Demographic Surveillance System (20%) ^{18–20} and Kiambu (13%)

250 (Supplementary Fig. 1). Percentage of SARS-CoV-2 lineage frequencies for circulating variants

in Kenya, Europe, and worldwide collected during the period of interest was based on data from

the Global Initiative on Sharing Avian Influenza Data (GISAID) as of 4th June 2024 ²¹. The

sequences collected and sequenced in Kenya during this period were downloaded in a multifasta

file and used to construct phylogenetic trees 18,19 .

255 Sample sets

To evaluate population immunity against the emerging variants, we took advantage of 256 257 residual samples collected in the Kenya Multi-site Integrated Sero-surveillance study in the period of September to December 2022 (n=30) and July to October 2023 (n=30) ^{22,23}. This study was 258 approved by the Scientific Ethics Review Unit (SERU) under identification numbers 4085 and 259 4807. An inclusion criteria was the receipt of vaccination. We selected samples with well-260 documented information on vaccination such as a vaccination certificate or a short message service 261 received after vaccination. As a comparator, we assayed plasma from 20 vaccine naïve SARS-262 CoV-2 wildtype naturally exposed individuals with PCR-positive results and sampled \geq 7 days after 263 their PCR-positive diagnosis¹⁷. The vaccinated post-pandemic panel consisted of 58 individuals 264 265 sampled from the Kilifi and Nairobi Health and Demographic Surveillance System (HDSS) site ²². The HDSS participants who were confirmed for vaccination were further split according to the 266 267 number of doses received. A final classification of either one (n=20), two (n=19), or three doses 268 (n=19) was defined and used for assaying. Detailed demographic characteristics of participants are shown in Table 1. 269

270 *Pseudovirus production and neutralization assay*

The pseudovirus production and assay validation have been described before 24 . Briefly, a 271 lentiviral expression system was used to produce wildtype and omicron sublineages, EG.5.1, FY.4, 272 BA.2.86, JN.1, and JN.1.4 pseudoviruses. Three plasmids, coding for the MLV-gag/pol backbone, 273 luciferase, and full-length spike protein of the different variants were co-transfected into HEK293T 274 cells using PEI (Polysciences, 24765-1) to produce a single round of infection competent 275 276 pseudoviruses. The media were changed 24hrs post-transfection and the pseudovirus harvested 277 72hrs post-transfection. The pseudoviruses were aliquoted and frozen for long-term storage. Virus infectivity of the variants was determined by titration on HEK293T (hACE2-hTMPRSS2)-stable 278 279 cells and dilution of pseudoviruses giving >20,000RLU was selected for assaying. To test for neutralization, 50 μ L of virus was immediately mixed with 50 μ L of serially diluted (2×) serum 280 and incubated for 1 h at 37°C. Following the incubation, 10,000 HEK293T (hACE2-hTMPRSS2) 281 282 cells/well (in 100 µL of media) were directly added to the antibody-virus mixture. The plates were 283 then incubated at 37°C for 72 h. To check for neutralization, HEK293T (hACE2-hTMPRSS2) cells 284 were lysed using a lysis buffer (Promega, E2661). Luciferase intensity was then read on a Luminometer with luciferase substrate according to the manufacturer's instructions (Promega, 285 E2650). The percentage of neutralization was calculated using the following equation: $100 \times (1 -$ 286 287 (RLU of sample-average RLU of background)/average RLU of virus only - average RLU of background)), where the background was cell-only control. Additionally, as part of the assay 288 289 controls, a positive control of a pool of convalescent serum from 50 individuals with confirmed 290 COVID-19 and a negative control of a pool of pre-pandemic serum from 50 individuals were 291 included. To determine the ID50 value, a model of the dose-response curve was fit using the 292 sample dilution and the corresponding neuralization percentage.

294 Statistical analysis

295		Data analysis was run on R v4.3.2 and R Studio 2023.12.1. ID ₅₀ significance was measured
296	using	g Student's t-test and Mann-Whitney tests, where significance was considered at p-value <
297	0.05	(*), p-value <0.001(**), and p-value <0.0001(***). The calculation of ID50 is as described
298	previ	ously ²⁴ .
299		
300	Refe	rences
301	1.	Altawalah, H. Antibody responses to natural sars-cov-2 infection or after covid-19 vaccination.
302		Vaccines (Basel) 9, (2021).
303	2.	Herzberg, J. et al. SARS-CoV-2-antibody response in health care workers after vaccination or
304		natural infection in a longitudinal observational study. Vaccine 40, (2022).
305	3.	Lotfi, M., Hamblin, M. R. & Rezaei, N. COVID-19: Transmission, prevention, and potential
306		therapeutic opportunities. Clinica Chimica Acta vol. 508 Preprint at
307		https://doi.org/10.1016/j.cca.2020.05.044 (2020).
308	4.	Changrob, S. et al. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by
309		Antibodies Targeting Distinct Epitopes on Spike. mBio 12, (2021).
310	5.	Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the
311		N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, (2021).
312	6.	Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
313		Nature 584, (2020).
314	7.	Uyoga, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.
315		Science (1979) 371 , (2021).

316	8.	Ogbe, A. T. et al. ChAdOx1 nCoV-19 VACCINATION in PWH: IMMUNE RESPONSES to
317		SARS-CoV-2, VOCs, and HCoVs. Top Antivir Med 30, (2022).
318	9.	Chibwana, M. G. et al. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive
319		antibody responses in Malawian adults previously infected with SARS-CoV-2. BMC Med 20,
320		(2022).
321	10.	Valleriani, F. et al. Neutralization of sars-cov-2 variants by serum from bnt162b2 vaccine
322		recipients. Viruses 13, (2021).
323	11.	MINISTRY OF HEALTH KENYA COVID-19 VACCINATION PROGRAM-Daily Situation Report:
324		Current Status Total Doses Administered; accessed on June 18, 2024.
325	12.	Nasimiyu, C. et al. Near-Complete SARS-CoV-2 Seroprevalence among Rural and Urban
326		Kenyans despite Significant Vaccine Hesitancy and Refusal. Vaccines (Basel) 11, (2023).
327	13.	Bates, T. A. et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral
328		response and antibodies that effectively neutralize variants. Sci Immunol 7, (2022).
329	14.	WHO: Statement on the antigen composition of COVID-19 vaccines. Statement on the antigen
330		composition of COVID-19 vaccines (who.int); accessed on June 18, 2024.
331	15.	Abdoli, A., Jamshidi, H., Taqavian, M., Baghal, M. L. & Jalili, H. Omicron-specific and bivalent
332		omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model. Sci
333		<i>Rep</i> 14 , (2024).
334	16.	Cerqueira-Silva, T., Boaventura, V. S. & Barral-Netto, M. Effectiveness of monovalent and
335		bivalent COVID-19 vaccines. The Lancet Infectious Diseases vol. 23 Preprint at
336		https://doi.org/10.1016/S1473-3099(23)00379-1 (2023).

- 17. Widyasari, K., Jang, J., Kang, T. & Kim, S. Effectiveness of Bivalent Omicron-Containing Booster
- 338 Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-
- 339 CoV-2 Infection. *Viruses* **15**, (2023).
- 18. Lambisia, A. W. et al. Detection of a SARS-CoV-2 Beta-like variant in coastal Kenya after more
- than a year of disappearance. *Wellcome Open Res* **8**, (2023).
- 342 19. Mwanga, M. J. *et al.* New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H,
 343 Kilifi, Kenya, March-May 2023. *Emerg Infect Dis* 29, (2023).
- 344 20. Githinji, G. *et al.* The genomic epidemiology of SARS-CoV-2 variants of concern in Kenya.
 345 *medRxiv* (2022).
- 346 21. Khare, S. *et al.* GISAID's Role in Pandemic Response. *China CDC Wkly* **3**, (2021).
- 347 22. Kagucia, E. W. et al. SARS-CoV-2 seroprevalence and implications for population immunity:

348 Evidence from two Health and Demographic Surveillance System sites in Kenya, February–

349 December 2022. Influenza Other Respir Viruses 17, (2023).

- 350 23. Kagucia, E. W. *et al.* Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.
 351 *Gates Open Res* 8, 60 (2024).
- 352 24. Nyagwange, J. *et al.* Serum immunoglobulin G and mucosal immunoglobulin A antibodies from
 353 prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. *International*354 *Journal of Infectious Diseases* 127, (2023).
- 355 25. Uraki, R. *et al.* Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. *Cell*356 *Rep* 42, (2023).
- Qu, P. *et al.* Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip
 variants. *Cell* 187, 585-595.e6 (2024).

359	27.	Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages
360		combining increased fitness and antibody evasion. Nat Commun 15, (2024).
361	28.	Shah, M. & Woo, H. G. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger
362		Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. Front
363		<i>Immunol</i> 12 , (2022).
364	29.	Tang, H. et al. Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the
365		host. Signal Transduction and Targeted Therapy vol. 8 Preprint at https://doi.org/10.1038/s41392-
366		023-01449-w (2023).
367	30.	Magazine, N. et al. Mutations and Evolution of the SARS-CoV-2 Spike Protein. Viruses vol. 14
368		Preprint at https://doi.org/10.3390/v14030640 (2022).
369	31.	Jary, A. et al. Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or
370		Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies. Viruses 14,
371		(2022).
372	32.	Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews
373		Microbiology vol. 19 Preprint at https://doi.org/10.1038/s41579-021-00573-0 (2021).
374	33.	Cui, Z. et al. Structural and functional characterizations of infectivity and immune evasion of
375		SARS-CoV-2 Omicron. Cell 185, (2022).
376	34.	Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization
377		and protect against the BA.5 Omicron variant in mice. Nat Med 29, (2023).
378	35.	Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune
379		imprinting. <i>Nature</i> 625 , (2024).
380	36.	Kinoshita, H. et al. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with
381		Antibody Deficiency. J Clin Immunol 41, (2021).

382	37.	Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
383		COVID-19. <i>Cell</i> 183 , (2020).
384	38.	Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185,
385		(2022).

386

387 Acknowledgments

- 388 We thank all the sample donors for their contribution to the research. We also acknowledge all
- 389 GISAID data contributors whose genomic sequences and metadata this work is based on.

390 Funding

- 391 This research was funded in whole or in part by the Wellcome Trust (grants
- 392 226141/Z/22/Z, 226130/Z/22/Z, 227131/Z/23/Z & 227131/B/23/Z 226141/Z/22/Z and
- 393 226002/A/22/Z), MRC (MR/W005611/1, MR/Y004205/1), BBSRC (BBS/E/I/COV07001,
- BBS/E/I/00007031) and Bill and Melinda Gates Foundation (INV-039626). For the purpose of
- 395 Open Access, the author has applied a CC-BY public copyright license to any author accepted
- 396 manuscript version arising from this submission.

397 Author contribution

- 398 Conceptualization and methodology: JN. Investigation: BK, JN, DL, MK, AS, JG, AK, DA, BK,
- AM, AL, DO, RL, JN. Formal analysis: JN, DL, BK, GG. Resources and funding acquisition:
- 400 JN, IO, DB, GG, CS, EN. Writing, original draft preparation: DL, JN, BK. Writing, review and

401 editing: all authors

402 **Conflicts of interest**

403 The authors report no conflicts of interest

404 Ethics declaration

- 405 This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical
- 406 Research Institute (SERU ID: 4085 and 4807). Written informed consent was obtained from
- 407 participants for the collection, storage, and further use of their sample sets in the research.
- 408 Figure Legends

409 Figure 1: SARS-CoV-2 lineage frequency (%) between May 2023 and March 2024. This

- 410 figure presents worldwide, European, and Kenyan SARS-CoV-2 lineage frequency % maps from
- 411 GISAID . A. Shows the lineage frequency % in all countries (n = 775112) B. Shows the lineage
- 412 frequency % in Europe (n=232081). C. Shows the lineage frequency % in Kenya (n=616). The
- legends in A, B, and C show the top circulating variants in each region within the period of
- 414 interest, with the colors corresponding to the frequency. D. Shows the phylogenetic analysis of
- 415 616 sequences collected and sequenced from Kenya between May 2023 and March 2024. The
- 416 legend shows the lineages corresponding to the colors on the tree.

417 Figure 2: A comparison of inhibitory dilutions (ID₅₀) between wildtype and omicron

418 variants EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, in Kenyan population samples (n=78). A.

- 419 Represents the log ID_{50} between wildtype and EG.5.1 where 41/78 in EG.5.1 showed
- 420 neutralization. B. Represents the log ID_{50} between wildtype and FY.4 where 23/78 samples
- 421 showed neutralization. C. Represents the log ID_{50} between wildtype and BA.2.86 where 25/78

422	samples showed neutralization. D. Represents the log ID_{50} between wildtype and JN.1 where
423	29/78 samples showed neutralization. E. Represents the log ID_{50} between wildtype and JN.1.4
424	where 31/78 samples showed neutralization. The numbers above each variant plot represent the
425	mean ID_{50} compared to wildtype. F. Shows the statistical analysis of ID_{50} between wildtype and
426	each variant. A statistical significance of P< 0.0001 (***) was recorded between wildtype and all
427	strains, based on Mann-Whitney tests. The sample colors represent SARS-CoV-2 variants where
428	red is wildtype, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is
429	JN.1.4. The dotted line represents the cut-off neutralization ID_{50} of 10^1 .
430	Figure 3:Evaluation of naturally- acquired (n=20) and vaccine-induced immunity (n=58) in
431	Kenyan population samples. A & B. Shows neutralization (log ID ₅₀) after natural infection
432	(n=20) or vaccination with one dose (n=20), two doses (n=19), and three doses (n=19). The
433	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4,
433 434	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by
433 434 435	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***). The dotted line
433 434 435 436	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***). The dotted line represents the cut-off neutralization ID ₅₀ of 10^1 . C. Represents the distribution of ID ₅₀ based on
433 434 435 436 437	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***). The dotted line represents the cut-off neutralization ID ₅₀ of 10^1 . C. Represents the distribution of ID ₅₀ based on age between individuals administered with one, two, and three doses of vaccine. The dotted line
433 434 435 436 437 438	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P< 0.05 (*), P< 0.001 (**), and P< 0.0001 (***). The dotted line represents the cut-off neutralization ID ₅₀ of 10 ¹ . C. Represents the distribution of ID ₅₀ based on age between individuals administered with one, two, and three doses of vaccine. The dotted line separates individuals below and above 50 years old. D. Shows the distribution based on days
433 434 435 436 437 438 439	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P< 0.05 (*), P< 0.001 (**), and P< 0.0001 (***). The dotted line represents the cut-off neutralization ID ₅₀ of 10 ¹ . C. Represents the distribution of ID ₅₀ based on age between individuals administered with one, two, and three doses of vaccine. The dotted line separates individuals below and above 50 years old. D. Shows the distribution based on days post-vaccination with administering one, two, and three vaccine doses. The dotted line represents
433 434 435 436 437 438 439 440	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P< 0.05 (*), P< 0.001 (**), and P< 0.0001 (***). The dotted line represents the cut-off neutralization ID ₅₀ of 10 ¹ . C. Represents the distribution of ID ₅₀ based on age between individuals administered with one, two, and three doses of vaccine. The dotted line separates individuals below and above 50 years old. D. Shows the distribution based on days post-vaccination with administering one, two, and three vaccine doses. The dotted line represents a cut-off of 6 months after vaccination. C & D Circles represent one dose, boxes represent two
433 434 435 436 437 438 439 440 441	legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***). The dotted line represents the cut-off neutralization ID_{50} of 10^1 . C. Represents the distribution of ID_{50} based on age between individuals administered with one, two, and three doses of vaccine. The dotted line separates individuals below and above 50 years old. D. Shows the distribution based on days post-vaccination with administering one, two, and three vaccine doses. The dotted line represents a cut-off of 6 months after vaccination. C & D Circles represent one dose, boxes represent two doses, and triangles represent three boxes.

442

444 Tables

445 Table 1: Baseline characteristics of naturally infected and vaccinated cohort used in this

- study. The table provides details of the sex, age, vaccination status, and type of vaccine in this
- 447 cohort.

	AstraZeneca	Pfizer	Johnson &	Moderna	Mixed	Wildtype	Total
	(n=30)	(n=10)	Johnson	(n=6)	(n=2)	Infected	(n=78)
			(n=10)			(n= 20)	
Sex							
Male	15 (50%)	2 (25%)	5 (50%)	3 (50%)	0 (0%)	11 (55%)	36
Female	15 (50%)	8 (75%)	5 (50%)	3 (50%)	2 (100%)	9 (45%)	42
Age							
>18-60	24 (81%)	8 (75%)	8 (80%)	5 (75%)	2 (100%)	17 (85%)	64
>60	6 (19%)	2 (25%)	2 (20%)	1 (25%)	0 (0%)	3 (15%)	14
Vaccination							
1 dose	6 (23%)	4 (38%)	10 (100%)	0 (0%)	0 (0%)	0 (0%)	20
2 doses	14 (50%)	3 (38%)	0 (0%)	1 (25%)	1 (50%)	0 (0%)	19
3 doses	10 (27%)	3 (24%)	0 (0%)	5 (75%)	1 (50%)	0 (0%)	19